GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)
NCT07222189 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect78/100
StatusTERMINATED
PhasePHASE2
Lead sponsorSanofi
Last update2026-10-22
Public-record facts
| Intervention | balinatunfib (DRUG), balinatunfib-matching placebo (DRUG) |
|---|---|
| Condition | Colitis Ulcerative, Crohn's Disease |
| Enrollment | 7 |
| Why stopped | Business decision |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is terminated and was updated 2026-10-22.
- It is an interventional PHASE2 study with a named drug/drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT07222189. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.